- Home
- FHTX vs ALEC Comparison
FHTX vs ALEC Comparison
Compare FHTX & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- ALEC
- Stock Information
- Founded
- FHTX 2015
- ALEC 2013
- Country
- FHTX United States
- ALEC United States
- Employees
- FHTX N/A
- ALEC N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FHTX Health Care
- ALEC Health Care
- Exchange
- FHTX Nasdaq
- ALEC Nasdaq
- Market Cap
- FHTX 513.7M
- ALEC 454.5M
- IPO Year
- FHTX 2020
- ALEC 2019
- Fundamental
- Price
- FHTX $9.04
- ALEC $5.65
- Analyst Decision
- FHTX Strong Buy
- ALEC Strong Buy
- Analyst Count
- FHTX 5
- ALEC 6
- Target Price
- FHTX $16.00
- ALEC $17.75
- AVG Volume (30 Days)
- FHTX 123.1K
- ALEC 559.2K
- Earning Date
- FHTX 11-04-2024
- ALEC 11-06-2024
- Dividend Yield
- FHTX N/A
- ALEC N/A
- EPS Growth
- FHTX N/A
- ALEC N/A
- EPS
- FHTX N/A
- ALEC N/A
- Revenue
- FHTX $25,515,000.00
- ALEC $61,508,000.00
- Revenue This Year
- FHTX N/A
- ALEC N/A
- Revenue Next Year
- FHTX $15.40
- ALEC $96.01
- P/E Ratio
- FHTX N/A
- ALEC N/A
- Revenue Growth
- FHTX N/A
- ALEC N/A
- 52 Week Low
- FHTX $2.70
- ALEC $3.66
- 52 Week High
- FHTX $10.25
- ALEC $8.90
- Technical
- Relative Strength Index (RSI)
- FHTX 61.38
- ALEC 62.06
- Support Level
- FHTX $7.95
- ALEC $4.82
- Resistance Level
- FHTX $9.54
- ALEC $5.42
- Average True Range (ATR)
- FHTX 0.56
- ALEC 0.33
- MACD
- FHTX 0.19
- ALEC 0.08
- Stochastic Oscillator
- FHTX 82.08
- ALEC 71.61
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.